budesonide + prednisolone + azathioprine

Standart of care-Duzce University refers to the control treatment arm used in the XENIC clinical trial (NCT04734405), a Phase 3 study conducted by Duzce University comparing exclusive enteral nutrition to standard pharmacological therapy in adults with newly diagnosed ileocaecal Crohn's disease. The regimen is stratified by disease severity: patients with mild disease receive oral budesonide (9 mg/day), while those with moderate-to-severe disease receive oral prednisolone (1 mg/kg, maximum 40 mg/day) with a fixed taper over 10 weeks, supplemented with azathioprine (2 mg/kg). Budesonide and prednisolone are corticosteroids that exert anti-inflammatory effects by binding to the glucocorticoid receptor, whereas azathioprine is a thiopurine prodrug that inhibits purine synthesis and Rac1 activation, leading to the suppression of T-cell mediated immune responses.

Other names

Standart of care-Duzce UniversityStandart of care